Related references
Note: Only part of the references are listed.Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results
Jerzy P. Szaflarski et al.
EPILEPSIA (2018)
Interactions between cannabidiol and commonly used antiepileptic drugs
Tyler E. Gaston et al.
EPILEPSIA (2017)
Dravet syndrome and its mimics: Beyond SCN1A
Dora Steel et al.
EPILEPSIA (2017)
Long-term retention rates for antiepileptic drugs: A review of long-term extension studies and comparison with brivaracetam
Manuel Toledo et al.
EPILEPSY RESEARCH (2017)
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome
Orrin Devinsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome
Joshua S. Kaplan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Comparing Safety and Efficacy of Third-Generation Anti-epileptic Drugs: Long-Term Extension and Post-marketing Treatment
Charlotte S. Kwok et al.
CNS DRUGS (2017)
Treatment of Dravet Syndrome
Elaine C. Wirrell
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2016)
Mortality in Dravet syndrome: A review
Sharon Shmuely et al.
EPILEPSY & BEHAVIOR (2016)
Mortality in Dravet syndrome
Monica S. Cooper et al.
EPILEPSY RESEARCH (2016)
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial
Orrin Devinsky et al.
LANCET NEUROLOGY (2016)
Are cannabidiol and Δ9-tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
John M. McPartland et al.
BRITISH JOURNAL OF PHARMACOLOGY (2015)
Dravet syndrome in Sweden: a population-based study
Cecilia Rosander et al.
DEVELOPMENTAL MEDICINE AND CHILD NEUROLOGY (2015)
The incidence of SCN1A-related Dravet syndrome in Denmark is 1: 22,000: A population-based study from 2004 to 2009
Allan Bayat et al.
EPILEPSIA (2015)
Molecular Targets of Cannabidiol in Neurological Disorders
Clementino Ibeas Bih et al.
NEUROTHERAPEUTICS (2015)
Incidence of Dravet Syndrome in a US Population
Yvonne W. Wu et al.
PEDIATRICS (2015)
Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders
Orrin Devinsky et al.
EPILEPSIA (2014)
Prognostic, clinical and demographic features in SCN1A mutation-positive Dravet syndrome
A. Brunklaus et al.
BRAIN (2012)
Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures
Nicholas A. Jones et al.
SEIZURE-EUROPEAN JOURNAL OF EPILEPSY (2012)
Dravet syndrome as epileptic encephalopathy: evidence from long-term course and neuropathology
Claudia B. Catarino et al.
BRAIN (2011)
Cannabidiol Displays Antiepileptiform and Antiseizure Properties In Vitro and In Vivo
Nicholas A. Jones et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Spectrum of SCN1A gene mutations associated with Dravet syndrome: analysis of 333 patients
C. Depienne et al.
JOURNAL OF MEDICAL GENETICS (2009)
The spectrum of SCNIA-related infantile epileptic encephalopathies
Louise A. Harkin et al.
BRAIN (2007)
Inhibition of an equilibrative nucleoside transporter by cannabidiol: A mechanism of cannabinoid immunosuppression
Erica J. Carrier et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy
L Claes et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Share Paper
